Applied Therapeutics(US:APLT) Prnewswireยท2025-01-30 10:45Core Viewpoint - Applied Therapeutics, Inc. faced significant stock price declines following the issuance of a Complete Response Letter (CRL) from the FDA regarding its lead drug candidate, govorestat, indicating deficiencies in the clinical application [2]. Group 1: Stock Performance and Decline - On November 26, 2024, Applied Therapeutics' stock closed at $10.21 per share, but after the CRL announcement on November 27, it dropped to $8.57, marking an initial decline [2]. - The stock continued to fall dramatically, reaching $2.03 on November 29, 2024, and further declining to $1.75 by December 2, 2024, resulting in a total decline of over 80% from its pre-announcement price [2]. - Following the disclosure of a "warning letter" from the FDA on December 2, 2024, the stock price fell further to $1.69 on December 3, 2024, and continued to decline to $1.38 on December 4, 2024, and $1.29 on December 5, 2024 [2]. Group 2: Legal Action and Shareholder Information - Shareholders who purchased shares during the class period from January 3, 2024, to December 2, 2024, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments [1][2]. - The deadline for shareholders to register for the class action is February 18, 2025, and there is no cost or obligation to participate [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [3].